CAR-T Cell Manufacturing Using Soluble Anti-CD3 and Monocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The manufacturing process of engineered lymphocytes, particularly CAR-T cells, is costly and time-consuming due to the complexity and variability in apheresis sample composition, requiring precise steps like anti-CD3 and anti-CD28 antibody coating, which limits automation and increases production costs and variability.
Innovation Solution
A method for generating CAR-T cells by activating T cells with a soluble anti-CD3 antibody without anti-CD28, selecting monocytes, and incubating them with T cells before transduction, optimizing the monocyte-to-T cell ratio, and modulating activation strength to reduce variability and enhance automation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Extent of automation
If traditional CAR-T cell manufacturing methods are used with anti-CD3 and anti-CD28 antibody coating, then T cell activation is achieved, but manufacturing complexity increases and automation is limited
Solution Approach 1:
The patent removes the anti-CD28 antibody coating step from the traditional T cell activation protocol, extracting only the essential anti-CD3 antibody coating requirement. This simplification eliminates a complex manufacturing step while maintaining T cell activation functionality, thereby enabling automation.
Solution Approach 2:
The patent changes the activation parameters by using soluble anti-CD3 antibody instead of coated anti-CD3 and anti-CD28 antibodies. This parameter change reduces the number of required reagents and steps, making the process more suitable for automated manufacturing systems.
2Ease of manufacture
If traditional CAR-T cell manufacturing methods are used with multiple antibody coatings, then T cell activation is achieved, but production cost increases
Solution Approach 1:
The patent extracts and removes the anti-CD28 antibody from the activation protocol, reducing reagent consumption. This elimination of a costly reagent directly reduces production costs while maintaining the essential T cell activation function through anti-CD3 antibody alone.
3Reliability
If traditional CAR-T cell manufacturing methods are used with variability in apheresis sample composition, then T cell production is achieved, but performance variability increases
Solution Approach 1:
The patent changes the activation approach from multiple antibody coatings to soluble anti-CD3 antibody treatment, creating a more standardized and controllable process parameter. This reduces the impact of apheresis sample composition variability on final CAR-T cell performance, improving batch-to-batch consistency.
4Productivity
If traditional CAR-T cell manufacturing methods are used with multiple activation steps, then T cell activation is achieved, but manufacturing time increases
Solution Approach 1:
The patent extracts and eliminates the anti-CD28 antibody coating step, reducing the number of activation steps required. This time-saving extraction maintains essential T cell activation while accelerating the manufacturing cycle, improving productivity.
Solution Approach 2:
The patent employs preliminary action by using soluble anti-CD3 antibody that can be rapidly applied without requiring complex coating procedures. This preliminary activation step can be performed quickly, reducing the overall manufacturing time while ensuring adequate T cell activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces production costs, enhances process efficiency, and minimizes variability in CAR-T cell performance by eliminating the need for anti-CD28 antibodies, allowing for more standardized and automated manufacturing.
Implementation Method 1
incubating the selected monocytes with the selected T cells prior to transduction of the T cells
Implementation Method 2
activating T cells selected from an apheresis sample by using a soluble anti-CD3 antibody
Data Source
AI summary
Provided herein are improvements to the conventional CAR-T cell manufacturing process. Specifically, the instant disclosure is related to processes for generating CAR-T cells by activating T cells selected from an apheresis sample by using a soluble anti-CD3 antibody, and without the use of an anti-CD28 antibody. The method includes the selection of monocytes from the apheresis sample and incubating the selected monocytes with the selected T cells prior to transduction of the T cells.